Blog

Shabnam Eghbali on Metastatic Melanoma treated with IO therapy – Vanderbilt Hem/Onc

Shabnam Eghbali/LinkedIn

Nov 12, 2024, 13:38

Shabnam Eghbali on Metastatic Melanoma treated with IO therapy – Vanderbilt Hem/Onc

Vanderbilt Hem/Onc shared a post on X:

“Dr. Shabnam Eghbali, PGY-2, Vanderbilt University Medical Center presented her work in metastatic Melanoma Society for Immunotherapy of Cancer SITC2024 treated with IO therapy:

LILRB RNA expression = (+) prognostic biomarker.
LILRB3 and LILRB4 leads to PFS/OS.”

Shabnam Eghbali on Metastatic Melanoma treated with IO therapy - Vanderbilt Hem/Onc

cancer immunotherapy IO therapy metastatic melanoma OncoDaily Oncology prognostic biomarker Shabnam Eghbali SITC2024 Vanderbilt Hem / Onc Vanderbilt University Medical Center

NEW PAPER ALERT: Efficacy of CDK4/6 Inhibitors and Endocrine Therapy in HR+/HER2- Advanced Breast Cancer by PAM50 Subtype: SOLTI-1801 CDK-PREDICT Results

Oncologist Near Me – Fabrice André: Leading Expert in Breast Cancer

Funding Impactful Cancer Research That Might Otherwise Go Unsupported: Ryan Schoenfeld on the Secret Behind Mark Foundation’s Success

One Hand Gives, Another Takes? Trump, Musk, Congress and Childhood Cancer Research Funding

Fabrice André has been elected as the President of the ESMO for the term 2025-2026

Special Coverage